An Open-Label Study of Nefazodone Treatment of Major Depression in Patients with Congestive Heart Failure
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objectives: To evaluate the feasibility of screening and recruiting patients with major depression and congestive heart failure (CHF) in a tertiary care cardiology hospital and to obtain preliminary efficacy, tolerability, and safety data for nefazodone treatment of a major depressive episode in CHF patients. Method: We conducted a 12-week, open-label trial of nefazodone given in dosages up to 600 mg daily. We assessed patients at baseline, 1, 2, 4, 8, and 12 weeks. Measures used were the 17-item Hamilton Depression Rating Scale (HDRS), the Clinical Global Impression Scale, the Beck Depression Inventory, Spielberger's State-Trait Anxiety Inventory, and the Minnesota Living with Heart Failure Questionnaire. We also obtained pre- and poststudy ECGs, 24-hour Holter monitor recordings, and plasma levels of norepinephrine. Results: After screening 443 CHF patients, 28 patients with major depression met study eligibility criteria. The 23 patients who completed 4 or more weeks of medication showed significant improvement on all depression scales and in quality of life. Of 19 subjects who completed the full 12-week trial, 74% experienced a decline of 50% or more on HDRS scores. The completers also showed a significant reduction in heart rate, an increase in QT intervals (but not in the QTc), and a marginally significant decrease in plasma norepinephrine. There were no changes in heart rate variability. Conclusions: It is feasible to screen and recruit CHF patients with major depression for an antidepressant trial. Nefazodone seems sufficiently safe, tolerable, and efficacious to justify a larger, placebo-controlled trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sertraline treatment of major depression in patients with acute MI or unstable angina
Glassman, A. H. (2002) · JAMA · doi:10.1001/jama.288.6.701 · Cited by 1,414
Jiang, W., Alexander, J., Christopher, E., Kuchibhatla, M., Gaulden, L. H., Cuffe, M. S., Blazing, M. A., Davenport, C., Califf, R. M., Krishnan, R. R., et al. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.15.1849 · Cited by 934 · cited 2×
“epression is associated with worse cardiac prognosis following hospitalization for myocardial infarction (MI) (1–3), unstable angina (4), cardiac catheterization (5), bypass surgery (6), and congestive heart failure (CHF) ( 7 ).”
BackgroundAdverse consequences of high sympathetic nervous activity in the failing human heart
Kaye, D. M., Lefkovits, J., Jennings, G. L., Bergin, P., Broughton, A., & Esler, M. D. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00332-0 · Cited by 665 · cited 1×
“Increased noradrenergic outflow is associated with worse prognosis in post-MI patients (14) and in patients with CHF (15, 16 ).”
Background
Cited by
Rutledge, T., Reis, V. A., Linke, S. E., Greenberg, B. H., & Mills, P. J. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.055 · Cited by 1,513
Safety and Efficacy of Sertraline for Depression in Patients With Heart Failure
O'Connor, C. M., Jiang, W., Kuchibhatla, M., Silva, S. G., Cuffe, M. S., Callwood, D. D., Zakhary, B., Stough, W. G., Arias, R. M., Rivelli, S. K., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.068 · Cited by 535
Depression and Cardiovascular Disease: Healing the Broken-Hearted
Whooley, M. A. (2006) · JAMA · doi:10.1001/jama.295.24.2874 · Cited by 251
DuBois, C. M., Millstein, R. A., Celano, C. M., Wexler, D. J., & Huffman, J. C. (2016) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.15m01902 · Cited by 45
Treatment of depression in patients with congestive heart failure
Shapiro, P. A. (2009) · Heart Failure Reviews · doi:10.1007/s10741-007-9058-6 · Cited by 30
“There has been one open-label study of nefazodone treatment for depression in heart failure [31].”
Background
Metadata
- Authors
- Lespérance, F., Frasure-Smith, N., Laliberté, M.-A., White, M., Lafontaine, S., Calderone, A., Talajic, M., & Rouleau, J.-L.
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2003-11
- Volume
- 48
- Issue
- 10
- Pages
- 695-701
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- OpenAlex
- W2154187447
- Cited by
- 37
- References
- 3
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.